ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

123
Osteomyelitis: Osteomyelitis: Pathophysiology & Treatment Decisions Clifford B. Jones, MD Original Author: Clifford B. Jones, MD; March 2004 Revised February 2007 & February 2011

Transcript of ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Page 1: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Osteomyelitis:Osteomyelitis:Pathophysiology &

Treatment Decisions

Clifford B. Jones, MD

Original Author: Clifford B. Jones, MD; March 2004 Revised February 2007 & February 2011

Page 2: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

“One Should Especially Avoid Such Cases if One has a Respectable

Excuse, for the Favorable Chances are Few and the Risks are Many….

Page 3: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

….Besides, if a Man does not Reduce the Fracture, He will be Thought Unskillful. If He does Reduce It, He will bring the Patient

Nearer to Death than Recovery.”

Hippocratic Writings, New York, Pelican Books, 1978

Page 4: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Fracture Management Goals

1. Osseous Union2. Restore Limb Function3. Avoid Complications

Page 5: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Osteomyelitis Results in:

1. Reduction in limb function2. Psychological & Social dysfunction3. Increased cost

Page 6: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Hansen’s 7 DsConcerning Prolonged Orthopaedic Problems

DespairDivorceDestitute

DepressionDelinquency

DefaultDeath

Sigvard Ted Hansen, 1997

Page 7: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Introduction• 350,000 long bone fxs/yr• Infection risk varies:

– Type I open – 10/1,000 infections– Type III open – up to 25%

Page 8: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Gustilo Open Fx ClassJBJS, 72A: 299-303, 1990

2%

7%

7%10-50%25-50%

Page 9: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Open Fractures

Type II Type IIIA

Type IIIB Type IIIB

Page 10: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Negative Biology of Open Fx

ContaminationCrushingStripping

DevascularizationComminution

Page 11: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Blood SupplyRhinelander, CORR, 1974

Page 12: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Blood SupplyRhinelander, CORR, 1974

Normal - endosteal/medullary 2/3-3/4internal external

Fracture - periosteal/external majorityinternal external

Periosteal Blood Supply Important

Page 13: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Centripetal FlowRhinelander, CORR, 1974

Page 14: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Initial Emergent Treatment

dTAntibiotics, IV

ReduceStabilize

Cover wound

Page 15: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Why infection risk high?Infection risk ≈ Fracture type (soft tissue)

Open fx = Contamination (70% cx +)

Open fx = Infected fx > 8 hours

Page 16: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Cost AnalysisInfection

– Increase cost 16-21%/pt– Increase hosp stay 36-50%/pt

Total Cost $ 271 million/yr

Page 17: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Definition• Group of conditions• “…presence of bacteria & an

inflammatory response causing progressive destruction of bone.”

– Fears, RL, et al, 1998

• “…suppurative process in bone caused by a pyogenic organism”

– Pelligrini, VD, et al, 1996

Page 18: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Why destruction of bone matrix?

Proteolytic enzymesHyperemiaOsteoclasts

Page 19: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Do Not Delay Tx & Dx

Page 20: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Classification• Waldvogel, 1971

– Classification based on pathogenesis

• May, 1989– 5 parts, post-traumatic tibial osteomyelitis

• Cierny & Mader, 1985– 4 factors affecting outcome– Host, site, extent of necrosis, degree of impairment

Page 21: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

PathogenesisWaldvogel, 1971

1. Hematogenous2. Contiguous focus of infection3. Direct inoculation

Page 22: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

AnatomicClassification(Cierny-Mader)

1985

I:I: II:II:

III:III: IV:IV:

Page 23: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Classification Break-DownI. Medullary

Endosteal nidus, min soft tissue involvement, ? Sinus tract

II. SuperficialSurface of bone, usu 2° to soft tissue defect

III. LocalizedLocalized sequestra, usu sinus tract, Usu stable s/p excision

IV. DiffusePermeative process, combination of I/II/III, Usu Unstable s/p excision

Page 24: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Physiologic Classification(Cierny-Mader, 1985)

A-Host: Good immune system & delivery

B-Host: Compromised hostBL: locally compromisedBS: systemically compromisedBC: combined

C-Host: Requires suppressive or no TxMinimal disabilityTx worse than dz, not a surgical candidate

Page 25: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Clinical Staging(Cierny-Mader, 1985)

Anatomic Type + Clinical StagePhysiologic ClassExample: IV BS tibial osteomyelitis = diffuse tibial lesion in a systemically compromised host

Page 26: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Types of Pathophysiology

Acute/Hematogenous

Chronic/Nonhematogenous

Page 27: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Acute/Hematogenous

• Anatomy (Hobo)– Sharp twist in metaphyseal capillaries

• Stasis (Trueta)– Decreased flow in capillaries & veins

• Combination (Morrissy)– Trauma & Bacteria

Page 28: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Acute/HematogenousProgression of Dz

• Cell death 2° to bacterial exotoxins bacterial culture medium worsens condition

Vascularity, leukocytosis, edema Pressure w/in rigid osseous container Pain, swelling, erythemaPotential for septic arthritis (knee, hip, shoulder)

Page 29: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Chronic/NonhematogenousS. aureus ↑

Pseudomonas aureginosa ↑Enterobacter

> 30% Polymicrobial> 30% Polymicrobial

Page 30: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Clinical Findings (varied)

ErythemaSwellingSinus TractDrainageLimpFluctuence

NoneNonePainPainTendernessTendernessFeverFeverHAHANausea/VomitingNausea/Vomiting

Page 31: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Clinical Findings• Must have high index of suspicion• Inappropriate use of Abx – obscure Sx• Must obtain Dx quickly

– If Tx started < 72°:• Decrease incidence of chronic osteomyelitis• Decrease destruction of bone

Page 32: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Laboratory DataAcute (Morrey, BF, OCNA, 1975)

WBC (25% of time)– Abnormal differential, Left Shift (65%)– Blood Cx – 50% positive

Chronic– Mild anemia, WESR, C-reactive protein– Possible leukocytosis with L shift– Blood Cx – usually negative

Page 33: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

RadiographsEarly – usu negative

Changes – delayed (10-21 days)

Page 34: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

RadiographsSoft Tissue

– Swelling, obscured soft tissue planes, haziness

Osseous– Hyperemia, demineralization– Lysis (when > 40% resorbed)– Periosteal reaction– Sclerosis (late)

Page 35: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Radionucleotide Imaging

99M Tc

67Ga

111In WBC

Page 36: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

99M Tc

• Action– binds to hydroxyapetite crystals

• Osteoblastic activity– Demineralized bone– Immature collagen

Page 37: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

99M Tc• 3 Phase Bone Scan

1. Radionucleotide angiogram2. Immediate post injection blood pool3. Three hour: soft tissue, urinary excretion

• Diagnosis– Cellulitis: Phases 1 &2, no change 3– Osteomyelitis: Phases 1 & 2, focal 3

• Results: 94% sensitivity, 95% specificity– Rosenthal 1992, Schauwecker 1992

Page 38: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Cellulitis

Page 39: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Osteomyelitis

Page 40: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

99M Tc: False Positive

DM foot d/oSeptic arthritis

Inflammatory bone dzAdjacent to pressure sores

Page 41: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

99M Tc4 Phase Bone Scan

• New development• Action:

– Mature bone: uptake stops at 4 hr– Immature woven bone: cont’d uptake at 24 hr

• Problem: needs f/u imaging at 24 hr (compliance)• Gupta 1988, Israel 1987, Schauwecker 1992

Page 42: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

67Ga

• Exudation of in vivo labeled serum protein– Transferrin, haptoglobin, albumin

• Results– 81% sensitivity, 69% specificity– Schauwecker, 1992

• Combination with Tc sensitivity, but specificity

Page 43: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

111In WBC

• Used in combination (Seabold, 1989)– In/Tc: 88% accurate– Ga/Tc: 39% accurate

• Preparation problem rad dose to spleen, 18-24hr delay

• Spine (Whalen, Spine 1991)– 83% false negative use MRI

Page 44: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

MRINo radiationGood soft tissue imagingImaging:

– T1 Dark– T2 Bright/Mixed

Page 45: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

T1 bright T2 dark

Page 46: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

T1 bright T2 dark

Page 47: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

MRI• Acute:

marrow fat granulation tissue H2O

• Chronic: thickened cortex– Low signal on all scans

• Cellulitis: no marrow changes

Page 48: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

MRI ResultsSchauwecker, 1992

• Sensitivity 92-100%• Specificity 89-100%• Excellent for Spine (Modic, RCNA, 1986)

– Sens 96%, Spec 92%, Accuracy 94%• Soft tissue extension• Sinus tract formation

– Bright Tx from skin to bone

Page 49: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

CT ImagingImage cortical and cancellous bone

Evaluate osseous adequacy of debridement

Page 50: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Aspiration BiopsyAcute

– Good, only 10-15% false negative

Chronic– Sinus tract cx: 76% sens, 80% spec– 70% with S aureus & Enterococcus– 30% Pseudomonas– Does not determine correct Abx

Page 51: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Acute/Hematogenous

Page 52: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Changing Bacterial Pathogens

Page 53: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Resistant Bacterium - ESKAPE

E Enterococcus faecuimS Staphlococcus aureusK Klebsiella pneumoniaeA Acinobacter baumanniiP Pseudomonas aeruginosaE Enterobacter aerogenes

Page 54: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

MSSA & MRSA

• MSSA Change to β lactam

• MRSA Treat ≤ MIC

Page 55: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Gram Negative Rods - SPICE

S SerratiaP PseudomonasI Indole positiveC CitrobacterE Enterobacter

Page 56: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Gram Negative

Rods

Page 57: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Proionibacterium acnes• Axillary bacteria (sebaceous glands)• Treated with:

– 1st: PCN or vanco– 2nd: Macrolides & Fluoroquinolones

• Long incubation time• Call lab – culture 2 wks, gram positive rods• Especially important for shoulder:

– Nonunions– Infections

Page 58: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Multilocus Polymerase Chain reaction & Electrospray Ionization/Mass Spectrometry

• Bacterial or fungal DNA is amplified by polymerase chain reaction and introduced into a mass spectroscopy by electrospray ionization

• The amplification procedure uses 16 S primers, and the primers can be varied to detect fungi and antibiotic resistance genes (eg, mec A).

Page 59: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Multilocus Polymerase Chain reaction & Electrospray Ionization/Mass Spectrometry

• Although culturing bacteria takes days, amplifying DNA takes hours

• Accurate, rapid point-of-care devices would be ideal for clinical use

Page 60: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Treatment Preventation

• Antibiotics – correct organism• Debridement – until viable tissue obtained• Irrigation• Wound care/coverage• Osseous & soft tissue stability

– Fx stability– Dead space management

Page 61: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

New Oral Agents: MRSA

Zyvox/linazid po/iv ↓ plts

Synercid iv

Infectious Disease Consult

Page 62: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Stability Oxymoron

Hardware increased ↑ bacterial growth

&

Fracture stability (hardware) ↓ bacterial growth

Page 63: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Glycocalyx = “slime”

Remove hardware, exchange for new once infection under controlRemove hardware, exchange for new once infection under control

Page 64: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Dead Space Control

Page 65: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Abx IMN Materials & Methods

Research: Retrospective ReviewTime: 3 year period, 2 year F/U

Location: Level 1 Trauma Center

Page 66: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

PatientsAge: 37 (range 18-67)

Femurs (n=4)Closed n=2Open n=2

Tibia (n=28)Closed n=2Open n=26

II: 4/26IIIA: 12/26IIIB: 10/28

10/28 open tibial fx with rotational or FTT for coverage

Page 67: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Antibiotic NailInserted Avg. 3 mo. (range 2 day – 23 mo.)

2 bags PMMA2.O g Vancomycin2.4 g Tobramycin32 Fr Chest Tube

3.2 mm Guide Wire

Page 68: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Incise & Debride WoundI&D Wound

I&D Canal

Reamers, Vent Hole

Page 69: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Presentation

44 M44 M4 bacterium4 bacterium

CoccidiomycosisCoccidiomycosis2 prior known “flare ups”2 prior known “flare ups”

Page 70: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Antibiotic IMN

32 Fr Chest Tube2 bags PMMA2.0 Vancomycin2.4 Tobramycin

Insert under pressure into chest tube while still “wet”

Insert 3.2 mm ball tip guide rod

Remove plastic before PMMA too hot and melting plastic chest tube

Page 71: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Insert Abx IMN

Page 72: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Wait until IMN Insertion

Wound HealedLabs ImprovedAnabolic Host

Usually 4-8 wks

(Average 4-8 wks)(Average 4-8 wks)

Page 73: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example

Page 74: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org
Page 75: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Examples

Page 76: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Infected Tibial Nonunion

• 32 M• 2 ppd smoker• MCA 18 mo, 2 prior surgeries• Draining wound• “No one to take care of him”

– Translation No money

Page 77: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Presentation

Page 78: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Options

• Type IV BC

• Unstable with Osteo• Smoker, malnutrition• Local open wound

• Nothing• Revise with plate• Revise with nail• Revise with ex fix• Revise with Ilizarov• Amputation

Length +/-

Page 79: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Debridement of Skin & BoneDebridement of Skin & Bone

Page 80: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Dead Space Management

Page 81: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Stabilize NonunionStabilize Nonunion

Page 82: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Coverage of Wound

Page 83: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Lengthening Leg

Page 84: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Noncompliance - NonunionNoncompliance - Nonunion

Page 85: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Final – Healed with GraftingFinal – Healed with Grafting

Page 86: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Infected Tibial Nonunion

• 38 yo M• Snuff tobacco• 1 pint vodka/day• 6 mo MCA with IIIB open tibia

Type I BS

Page 87: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Presentation

Page 88: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Initial Post opInitial Post op

Page 89: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

3 mo

Page 90: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Exchange IMN at 4 ½ moExchange IMN at 4 ½ mo

Page 91: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Final at 18 moFinal at 18 mo

Page 92: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example• 54 yo Male• Post-operative Pseudomonas osteomyelitis• Refractory to HW removal & Ancef• Healthy, non-smoking• Cierny III A Host

Photos from M Swiontkowski

Page 93: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example 1

•Dead Space

•Calcaneal defect

Page 94: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example 1• Debridement of all non-viable bone with

laser doppler• Defect filled with antibiotic PMMA• 6 wks antibiotics

Page 95: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example 1, at 6 wks• Removal Abx beads• Bone grafting• Lateral arm flap• Infection eradication

Page 96: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example• 47 yo Male, smoker• Presentation 2 months s/p ORIF closed proximal

tibia fx• Draining wound• Exposed HW• Cierny III BC Host

• Photos from M Swiontkowski

Page 97: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example• Debridement• HW remains• Abx beads

Exposed plate

Page 98: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example • Gastrocnemeus flap, STSG

Page 99: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example • At 6 weeks• Remove Abx beads• Bone grafting• Healed wound and fracture

Page 100: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example• At 5 yo, tibial osteomyelitis• Partially treated• At 62 yo, presentation to MD• Chronic draining tibial osteomyelitis• Cierny III BC Host

• Photos from M Swiontkowski

Page 101: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example•Sinus tracts

•Chronic skin changes

Page 102: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example•I&D to normal bleeding bone with laser doppler

•Bx – negative for cancer

Page 103: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example• Abx beads• Latissimus Flap• STSG

Page 104: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Example• Removal Abx beads at 6 wks• No bone graft – low demand

patient• Dz free at 8 years (70 yo)

Page 105: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Outcomes of Treatment

Page 106: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Antibiotic IMN

Page 107: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org
Page 108: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org
Page 109: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

The Fate of Patients with a “Surprise” Positive Culture

After Nonunion Surgery

Olszewski D, Stucken C, Tornetta III P, Ricci W, Struebel P, Jones C, Sietsema D

Page 110: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Results• 460 patients

• Two cohort groups

– 98 cultures (21%) “surprise” positive

– 362 cultures (79%) negative

Page 111: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

BacteriaType of Bacteria Number

Coagulase-negative Staphylococcus 45

Methicillin-resistant S. Aureus 12

Pseudomonas 8

Proprionibacterium 8

Methicillin-sensitive S. Aureus 7

Bacillus 4

Peptostreptococcus 3

Staph species unspecified 3

Enterococcus 2

Strep viridans 2

Clostridium 2

E. coli, Staph epidermidis, Beta hemolytic strep,

Serratia, Candida and Aspergillus 1

Page 112: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Positive Cultures• 98 with positive cultures

– 90 treated with antibiotics

• 6 – 8 week duration

• Culture specific

– 8 patients not treated

• “Presumed contaminant”

Page 113: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Union After Index

• Culture (+) = 66 / 90 (73%)• Culture (-) = 347 / 362 (96%)• P < 0.0001

Page 114: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Infection After Index

• Culture (+) = 11 / 90 (12%)• Culture (-) = 15 / 362 (4%)• P < 0.0001

Page 115: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Final Outcome• Culture (+) = 86 / 90 (95.5%)

– 24 Additional procedures – 9 / 13 Debridement only– 4 / 13 with 1 additional procedure– 4 / 90 (4.5%) infected nonunion– 2 BKA

• Culture (-) = 362 / 362 (100%)– 15 Additional procedures

• P < 0.0001

Page 116: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

“Presumed Contaminants”• 8 “surprise” cultures not treated with antibiotics

– Deemed “contaminants”– 5 Healed– 3 Nonunions

• 1 Amputation• 1 Infected nonunion• 1 Non-infected nonunion

Page 117: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

  Culture Positive Culture Negative

Healed 73% 95.8%Infected Nonunion 13% 4%

Additional Procedures 27% 4%

Union at final follow-up

93% 100%

All Patients

Page 118: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Summary

• 21% of 460 “at risk” nonunions had surprise positive culture

• Staph species• 90 of 98 treated with antibiotics

Page 119: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Summary• Culture positive

–73% Index–93% Final

• Culture negative

–95.5% Index–100% Final

Page 120: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

“Surprise” cultures• Revision shoulder arthroplasty

– 17 to 29% “surprise” positives– 13 to 25% require re-revision

• Revision hip arthroplasty – 11% “surprise” positives– 13% require re-revision

1. Kelly II JD, Hobgood ER. Positive culture rate in revision shoulder arthroplasty. Clin Orthop Relat Res. 2009;467:2243-48.2. Topolski MS, Chin PY, Sperling JW, Cofield RH. Revision shoulder arthroplasty with positive intraoperative cultures: the value of preoperative

studies and intraoperative histology. J Shoulder Elbow Surg. 2006;15:402-406.3. Tsukayama DT, Estrada R, Gustilo RB. Infection after total hip arthroplasty: a study of the treatment of one hundred and six infections. J Bone

Joint Surg Am. 1996;78:512-523.

Page 121: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Conclusions• 21% “surprise” positive cultures• 74% heal after initial index

procedure• 26% required additional procedures

Page 122: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Recommendations

• Counsel patients• Treat all positive cultures• Potentially offer two-stage procedures

– Unknown efficacy– 79% would be unnecessary

Page 123: ota.orgota.org/media/29281/G19_Osteomyelitis.ppt · 2016-03-26ota.org

Conclusion

PreventionEarly DxEarly TxStabilize

Convert to Union ASAP

Return to General/Principles

Index

If you would like to volunteer as an author for the Resident Slide Project or recommend updates to any of the following slides, please send an e-mail to [email protected]